Neuromodulation : journal of the International Neuromodulation Society
-
We evaluated trends in deep brain stimulation (DBS) for the 14-year period from 1993 to 2006. ⋯ Future studies will need to include the socioeconomic impact of the technology on disease status, patient access, and costs as it expands to novel indications.
-
This study aimed to assess the long-term results of deep brain stimulation (DBS) for patients affected with Gilles de la Tourette syndrome, documenting refractoriness to conservative treatments. ⋯ Gilles de la Tourette syndrome is a complex neuropsychiatric disorder with a significant prevalence in the general population. More than 50% of the patients with TS present a behavioral comorbidity, and anxiety and depression are, to various degrees, associated to this "waxing and waning" clinical picture. DBS in our experience proved to be a valid treatment modality for those patients who fail to respond to conservative treatment modalities. A multidisciplinary team is nevertheless necessary to properly handle this complex therapeutic option.
-
Successful treatment of charcot-marie-tooth chronic pain with spinal cord stimulation: a case study.
Charcot-Marie-Tooth (CMT) disease is one of the most common hereditary neuropathies affecting one in 2500 people in the United States. CMT disease is associated with moderate to severe chronic extremity pain. We present the case of a young man with chronic intractable lower extremity pain associated with CMT disease treated with spinal cord stimulation (SCS). ⋯ SCS produced favorable results in a patient with CMT and should be considered a treatment option for pain resulting from this condition.
-
To summarize research to understand the priorities of consumers with spinal cord injury (SCI) as related to neuroprosthesis. ⋯ Understanding the consumer is the cornerstone to successful delivery of a neuroprosthesis. Translational research by multidisciplinary teams is needed to understand these issues and move technology for people living with SCI from the bench to the bedside.
-
In the present review article we summarize available clinical and preclinical evidence, if modulation of the subthalamic nucleus (STN) could be a target for neuroprotection in Parkinson's disease (PD). ⋯ Clear clinical evidence for STN-DBS-related neuroprotection in PD is missing. However, numerous preclinical studies show (and are discussed) that silencing of the STN via lesion or DBS may exert neuromodulative effects on nigral dopamine neurons.